The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study.
M. Martin
Other Remuneration - Roche
N. Martinez
No relevant relationships to disclose
M. Ramos
No relevant relationships to disclose
L. Calvo
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
P. Zamora
Honoraria - Roche
Research Funding - Roche
M. Munoz-Mateu
Other Remuneration - Roche
D. Caronia
No relevant relationships to disclose
E. M. Carrasco
Consultant or Advisory Role - Lilly (U)
Stock Ownership - Lilly
Honoraria - Lilly
J. Á. Garcia Saenz
No relevant relationships to disclose
A. Casado
No relevant relationships to disclose
I. Chacón
Honoraria - Roche
B. Hernando
No relevant relationships to disclose
M. Ruiz-Borrego
Other Remuneration - Roche
A. Gonzalez-Neira
No relevant relationships to disclose